INBX
Inhibrx Biosciences Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +0.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +7 | 7.66M | $725.26M | +12 | −5 |
| Q1 2026 | 65 | -3 | 7.61M | $511.38M | +3 | −7 |
| Q4 2025 | 69 | 0 | 8.07M | $637.42M | +2 | −1 |
| Q3 2025 | 17 | +7 | 4.45M | $150.05M | +7 | n/a |
| Q2 2025 | 7 | 0 | 3.86M | $55.09M | n/a | n/a |
| Q1 2025 | 4 | -1 | 2.48M | $34.64M | n/a | −1 |
| Q4 2024 | 5 | -2 | 2.53M | $38.98M | n/a | −2 |
| Q3 2024 | 6 | +1 | 2.46M | $38.48M | +2 | −1 |
| Q2 2024 | 5 | n/a | 2.53M | $35.86M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 1.79M | 0.0% | $25.51M | 0.1% | Held | 5 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 728.74K | n/a | $10.40M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 598.45K | n/a | $8.54M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Millennium Management ✦ | 275.78K | +8.0% | $3.94M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 225.96K | -13.1% | $3.23M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 204.96K | +18.5% | $2.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Fidelity (FMR) ✦ | 39.07K | n/a | $557,538 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 134 holders, 12.71M shares, $853.40M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Chief Executive… · 2.47K sh @ 84.07 · $207,655
Officer, Director · Chief Executive… · 100 sh @ 85.76 · $8,576
Officer, Director · Chief Executive… · 2.45K sh @ 85.00 · $208,333
Officer, Director · Chief Executive… · 2.45K sh @ 84.07 · $205,889
Officer, Director · Chief Executive… · 100 sh @ 85.76 · $8,576
Officer, Director · Chief Executive… · 2.47K sh @ 85.00 · $209,948
Officer, Director · Chief Executive… · 3.00K sh @ 101.70 · $305,106
Officer, Director · Chief Executive… · 1.50K sh @ 98.88 · $148,320
Officer, Director · Chief Executive… · 2.18K sh @ 99.60 · $216,727
Officer, Director · Chief Executive… · 3.32K sh @ 98.87 · $328,630
Open-market sales (S)
Director · 500 sh · $52,525
Director · 500 sh · $55,130
Director · 500 sh · $55,888
Director · 500 sh · $57,898
Director · 500 sh · $57,570
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology